Shimizu Hiroaki, Nukui Yuji, Mitsuhashi Noboru, Kimura Fumio, Yoshidome Hiroyuki, Ohtsuka Masayuki, Kato Atsushi, Miyazaki Masaru
Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
J Surg Res. 2009 Jun 1;154(1):60-7. doi: 10.1016/j.jss.2008.05.035. Epub 2008 Jul 29.
Most malignancies lack tumor-associated antigens, which are recognized by T-lymphocytes through major histocompatibility complex (MHC) molecules, and seem to evade host immunological defense. In this study, we investigated whether allogeneic MHC gene transfer into the low-antigenic tumor might induce cell-mediated immunity, and provide an immunotherapeutic effect in vivo.
Mammary adenocarcinoma cells (MAT B III) originated from an F344 rat (RT1A(l)) were transfected with a plasmid DNA encoding RT1A(a) (pcMRT1A) in vitro. Cytolytic T-cell response was then evaluated using F344 splenocytes. Furthermore, pcMRT1A-liposome complex was injected into the MAT B III tumors grown in F344 rats, followed by a series of eight electrical pulses with a electroporator, every other d for total of four times. The tumor size and survival of animals were evaluated thereafter.
The expression of RT1A(a) on the tumor cells induced cytolytic T-cell response in vitro. Intratumor injection of pcMRT1A-liposome complex followed by in vivo electroporation markedly generated biological response, including increased interferon-gamma (IFN-gamma) expression and a large number of infiltrated cells in the tumor. Inhibited tumor growth, even complete tumor regression, was observed, resulting in prolonged survival time.
Direct transfer of allogeneic MHC gene into the tumor by in vivo electroporation could induce a cell-mediated immune response against the introduced antigens, resulting in local IFN-gamma production. This initial response may bring about the subsequent immunological response even to the unmodified tumor cells through cytokines such as IFN-gamma, resulting in the marked tumor regression.
大多数恶性肿瘤缺乏肿瘤相关抗原,而肿瘤相关抗原可通过主要组织相容性复合体(MHC)分子被T淋巴细胞识别,因此这些肿瘤似乎能够逃避宿主的免疫防御。在本研究中,我们调查了将同种异体MHC基因转移至低抗原性肿瘤中是否可诱导细胞介导的免疫反应,并在体内产生免疫治疗效果。
源自F344大鼠(RT1A(l))的乳腺腺癌细胞(MAT B III)在体外被编码RT1A(a)的质粒DNA(pcMRT1A)转染。然后使用F344大鼠脾细胞评估细胞毒性T细胞反应。此外,将pcMRT1A -脂质体复合物注射到F344大鼠体内生长的MAT B III肿瘤中,随后使用电穿孔仪每隔一天进行一系列八次电脉冲处理,共进行四次。此后评估动物的肿瘤大小和存活率。
肿瘤细胞上RT1A(a)的表达在体外诱导了细胞毒性T细胞反应。瘤内注射pcMRT1A -脂质体复合物并进行体内电穿孔后显著产生了生物学反应,包括肿瘤中干扰素 -γ(IFN -γ)表达增加和大量浸润细胞。观察到肿瘤生长受到抑制,甚至肿瘤完全消退,从而延长了存活时间。
通过体内电穿孔将同种异体MHC基因直接转移至肿瘤中可诱导针对引入抗原的细胞介导免疫反应,导致局部产生IFN -γ。这种初始反应可能通过IFN -γ等细胞因子引发针对未修饰肿瘤细胞的后续免疫反应,从而导致肿瘤显著消退。